| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3188943 | Annales de Dermatologie et de Vénéréologie | 2009 | 9 Pages |
Abstract
The therapeutic progress is primarily due to an explosion of biological therapies, particularly four of them very useful for internists (in an off label use) : Interleukin 1 inhibitors (anakinra, Canakinumab) to treat some auto inflammatory diseases (cryopirin associated periodic syndromes and deficency of interleukin 1 receptor antagonist), monoclonal antibody against interleukin 5 (mepolizumab) to treat some hypereosinophilic syndromes and Churg and Strauss angiitis, interleukin 6 inhibitiors to treat multifocal Castleman's disease and adult Still disease, a monoclonal antibody against vascular endothelial growth factor (Bevacizumab) to treat hereditary hemorrhagic telangiectasia.
Related Topics
Health Sciences
Medicine and Dentistry
Dermatology
Authors
O. Blétry, T. Sene, J.-E. Kahn, F. Ackermann, P. Charles, J. Leport, A.-M. Piette,